DR. WENDY S REEVES M.D.
Prescription History 1003045014
Obstetrics & Gynecology in Scottsbluff, NE


Quality Rating: 76.99 out of 100 score

NPI Status: Active since July 11, 2009

Contact Information

3911 AVENUE B STE 3100
SCOTTSBLUFF, NE
ZIP 69361
Phone: (308) 635-3033
Fax: (308) 635-3010

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. WENDY S REEVES M.D., an active Obstetrics & Gynecology specialist practicing in Scottsbluff, NE. Our medical registry currently tracks 2 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 45 documented patient claims. Among these therapy options, the most frequently utilized medication is Myrbetriq, which accounts for 26 claims alone.

Medication Index

No matching medications currently found on file.

Estradiol

Generic Formulation: EstradiolSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 19
30-Day Fills 52.0
Days Supply 1,527
NE State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills58.7
Peer Average Days Supply1,747
Conservative Utilization

This provider writes prescriptions for this formulation 29.6% less frequently than the standard regional baseline metric for practitioners inside NE. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,912.00 across this reporting matrix range.

Provider Avg Cost Per Claim

$100.63

State Avg Cost Per Claim

$52.12

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids.

Therapeutic Applications

This medication is a female hormone (estrogen). It is used by women to help reduce symptoms of menopause (such as hot flashes, vaginal dryness). These symptoms are caused by the body making less estrogen. If you are using this medication to treat symptoms only in and around the vagina, products applied directly inside the vagina should be considered before medications that are taken by mouth, absorbed through the skin, or injected. This medication may also be used by women who are not able to produce enough estrogen (for example, due to hypogonadism, primary ovarian failure). Certain estrogen products may also be used by women after menopause to prevent bone loss (osteoporosis). However, there are other medications (such as raloxifene, bisphosphonates including alendronate) that are also effective in preventing bone loss and may be safer. These medications should be considered for use before estrogen treatment.

Myrbetriq

Generic Formulation: MirabegronSpecialty: Obstetrics & Gynecology
Provider Metrics Summary
Total Claims 26
30-Day Fills 26.0
Days Supply 364
NE State Average Benchmarks
Peer Average Claims42.0
Peer Average 30-Day Fills52.6
Peer Average Days Supply1,363
Conservative Utilization

This provider writes prescriptions for this formulation 38.1% less frequently than the standard regional baseline metric for practitioners inside NE. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,778.08 across this reporting matrix range.

Provider Avg Cost Per Claim

$222.23

State Avg Cost Per Claim

$492.58

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain bladder problems (overactive bladder, neurogenic detrusor overactivity). Overactive bladder is a problem with how your bladder stores urine. Neurogenic detrusor overactivity is a bladder control condition caused by brain, spinal cord, or nerve problems. Symptoms of these conditions may include frequent urination, strong sudden urges to urinate that are hard to control, or involuntary loss of urine (incontinence). Mirabegron works by relaxing a certain bladder muscle (detrusor), which helps the bladder hold more urine and lessens symptoms of overactive bladder and neurogenic detrusor overactivity.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. WENDY S REEVES M.D. provides transparency into local medical care patterns within Scottsbluff, NE.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Obstetrics & Gynecology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.